Background: Periosteal osteosarcoma is a rare surface-based variant with a lower propensity to metastasis and better prognosis than conventional osteosarcoma. The literature supporting survival benefit with adjuvant chemotherapy is lacking. Our institutional practice is for chemotherapy to be offered to patients with high-grade disease.
Methods: We conducted a retrospective cohort study of patients managed for periosteal osteosarcoma from 1970 to 2015 analyzing the survival outcomes and assessing for any relationship of survival to patient- or treatment-related factors. 18 patients were included. The study population presented at a mean of 20.8 years and was followed for a mean of 10.7 years. Factors assessed for an association with survival included age, size of tumor, use of chemotherapy, presence of medullary involvement, presence of high-grade disease, local recurrence, and site of disease. Kaplan-Meier survival analysis and Cox proportional hazard regression were performed to calculate the survival rates and to assess for the effect of any factor on survival.
Results: 10-year overall survival rate was 77.1%, and 10-year event-free survival rate was 66.4%. No factor was found to have an association with overall or event-free survival.
Conclusion: These findings add to the available evidence which has failed to find any survival benefit from chemotherapy; patients with this rare disease and their families should be counselled regarding the unclear role of chemotherapy in this rare subtype of osteosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180962 | PMC |
| http://dx.doi.org/10.1155/2018/8631237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demographic and Treatment Analysis of Periosteal Osteosarcoma.
Cancer Rep (Hoboken)
December 2024
Brody School of Medicine (BSOM), East Carolina University (ECU), Greenville, North Carolina, USA.
Background And Aims: Periosteal osteosarcoma (PO) is a rare bone cancer that makes up between 1% and 6% of osteosarcomas. No epidemiological survey of the United States has been conducted to study this disease, and most of the literature is limited to single-center analyses and case reports. We seek to perform the first such assessment.
View Article and Find Full Text PDFSilent surface osteosarcoma treated following the hemi-capanna technique. A case report.
Acta Ortop Mex
November 2024
Equipo, Hospital Clínico San Carlos, Madrid España.
Introduction: surface sarcomas are a rare entity that need correct diagnosis to differentiate parosteal (cPOS), periosteal and the high grade surface osteosarcomas (HGSO). HGSO has malignant behavior similarities with osteosarcomas and wide resection is the key to a successful treatment.1 The Capanna and Hemi-Capanna reconstruction techniques have being developed in order to avoid amputation after an oncological resection, allowing structural support from an allograft and biological advantages from a vascularised autograft.
View Article and Find Full Text PDFImaging of Osteosarcoma: Presenting Findings, Metastatic Patterns, and Features Related to Prognosis.
J Clin Med
September 2024
Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
Article Synopsis
- Osteosarcomas are rare bone tumors that make up less than 1% of all cancers and are most commonly found in children, second only to multiple myeloma among primary bone tumors.
- The imaging characteristics of osteosarcomas vary by histological subtype, with conventional types showing mixed radiological patterns and aggressive features, while telangiectatic forms are typically purely lytic.
- The review emphasizes the relationship between imaging features and patient outcomes, including treatment response and survival, highlighting important parameters for medical professionals involved in the management of these tumors.
Li-Fraumeni-associated osteosarcomas: The French experience.
Pediatr Blood Cancer
December 2024
Department of Children and Adolescents Oncology, Gustave Roussy Cancer, Paris-Saclay University, Villejuif, France.
Purpose: Describe clinical characteristics and outcome of Li-Fraumeni syndrome (LFS)-associated osteosarcomas.
Methods: TP53 germline pathogenic/likely pathogenic variant carriers diagnosed with osteosarcoma in France between 1980 and 2019 were identified via the French Li-Fraumeni database at Rouen University Hospital. Sixty-five osteosarcomas in 52 patients with available clinical and histological data were included.
Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS).
Pediatr Blood Cancer
December 2024
Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
Background: Osteosarcoma may arise as a secondary malignancy following rhabdomyosarcoma (RMS). We utilized the Cooperative Osteosarcoma Study Group (COSS) database to better understand this association.
Patients And Methods: The COSS database (1980-05/2023) was searched for patients whose osteosarcoma was preceded by RMS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!